<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04166305</url>
  </required_header>
  <id_info>
    <org_study_id>Mansoura University Hospital 6</org_study_id>
    <nct_id>NCT04166305</nct_id>
  </id_info>
  <brief_title>Drug Resistant Epilepsy: Clinical and Genetic Study</brief_title>
  <official_title>Clinical and Genetic Factors Associated With Drug Resistance of Epilepsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to identify the clinical criteria of drug resistant epilepsy and to explore
      whether SCN1A c.3184 A/G (rs2298771) and ccl2(rs1024611) polymorphisms could serve as genetic
      based biomarkers to predict drug resistance among epileptic patient.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This retrospective case control study will be conducted on 120 epileptic patients treated
      with AEDs, 60 patients are drug responders and 60 patients are drug resistant. All epileptic
      patient will be recruited from outpatient epilepsy clinic, Department of Neurology, Mansoura
      University hospital. The control consists of 60 Age and gender matched healthy individual
      with negative past and family history of epilepsy and febrile convulsion.

      Subjects:

      Inclusion criteria:

        1. Patient with diagnosis of epilepsy (idiopathic or cryptogenic/symptomatic), according to
           the International League Against Epilepsy classification confirmed by
           electroencephalogram.

        2. Treatment with at least one AED, long enough to achieve the optimal dose;
           drug-resistance and drug-responsiveness, according to the criteria ILAE 2010.

        3. Written consent obtained from a patient or legal guardian.

      Exclusion criteria:

        1. Patient with severe adverse anti epileptic drug reactions.

        2. Patient with unreliable records of seizure frequency.

        3. Patient with poor compliance with AEDs,.

        4. Patient with significant psychiatric comor- bidity,

        5. Patient with progressive systemic disorders .

        6. Patient with history of alcohol or drug abuse.

        7. Epileptic patients in clinical remission or with gradual withdrawal of therapy.

        8. Epileptic patients with therapy titration phase.

      Methods:

      After an informed consent, all participants will be subjected to the following;

        1. A detailed history taking; including age, sex, age of onset , type of seizure, duration
           of epilepsy, pretreatment and post treatment seizure frequency , and drugs
           (antiepileptic drugs, others).

        2. Full laboratory investigation including (complete blood count, liver function test,
           serum creatinine, electrolyte assay, thyroid profile, blood sugar test).

        3. Serum level of antiepileptic drug.

        4. Electroencephalogram in order to localize site of paroxysmal activity.

        5. MRI brain: T1, T2 and FLAIR: axial and coronal cuts to detect any structural
           abnormalities,

        6. Both control and epileptic patient will underwent genetic study for SCN1A c.3184 A/G and
           CCL2-2518G&gt;A polymorphism:

             -  DNA analysis:

      Genomic DNA will be extracted from EDTA-anticoagulated peripheral blood (QIAamp DNA Blood
      mini kit,QIAGEN).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Anticipated">November 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Genetic study for SCN1A c.3184 A/G and CCL2-2518G&gt;A polymorphism:</measure>
    <time_frame>5-7 days</time_frame>
    <description>• DNA analysis: Genomic DNA will be extracted from EDTA-anticoagulated peripheral blood (QIAamp DNA Blood mini kit,QIAGEN).
• Genotyping of SCN1A c.3184 A/G(rs2298771) polymorphism</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Epilepsy, Drug Resistant</condition>
  <arm_group>
    <arm_group_label>Drug responders</arm_group_label>
    <description>60 patients are drug responders</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug resistant</arm_group_label>
    <description>60 patients are drug resistant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>The control</arm_group_label>
    <description>The control consists of 60 Age and gender matched healthy individual with negative past and family history of epilepsy and febrile convulsion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Genetic study for SCN1A c.3184 A/G and CCL2-2518G&gt;A polymorphism:</intervention_name>
    <description>DNA analysis: Genomic DNA will be extracted from EDTA-anticoagulated peripheral blood (QIAamp DNA Blood mini kit,QIAGEN).
Genotyping of SCN1A c.3184 A/G(rs2298771) polymorphism</description>
    <arm_group_label>Drug resistant</arm_group_label>
    <arm_group_label>Drug responders</arm_group_label>
    <arm_group_label>The control</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This retrospective case control study will be conducted on 120 epileptic patients treated
        with AEDs, 60 patients are drug responders and 60 patients are drug resistant. The control
        consists of 60 Age and gender matched healthy individual with negative past and family
        history of epilepsy and febrile convulsion.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with diagnosis of epilepsy (idiopathic or cryptogenic/symptomatic), according
             to the International League Against Epilepsy classification confirmed by
             electroencephalogram.

          -  Treatment with at least one AED, long enough to achieve the optimal dose;
             drug-resistance and drug-responsiveness, according to the criteria ILAE 2010.

        Exclusion Criteria:

          -  Patient with severe adverse anti-epileptic drug reactions.

          -  Patient with unreliable records of seizure frequency.

          -  Patient with poor compliance with AEDs,.

          -  Patient with significant psychiatric comorbidity,

          -  Patient with progressive systemic disorders .

          -  Patient with history of alcohol or drug abuse.

          -  Epileptic patients in clinical remission or with gradual withdrawal of therapy.

          -  Epileptic patients with therapy titration phase.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Esmael M Ahmed, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistant Prof of Neurology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Esmael M Ahmed, MD</last_name>
    <phone>00201000372787</phone>
    <email>deltaneuro@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mansoura University Hospital</name>
      <address>
        <city>Mansoura</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esmael M Ahmed, MD</last_name>
      <phone>00201000382898</phone>
      <email>deltaneuro@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <results_reference>
    <citation>He X, Li Y, Liu Z, Yue X, Zhao P, Hu J, Wu G, Mao B, Sun D, Zhang H, Song X, Wang Y, Shao J. The association between CCL2 polymorphisms and drug-resistant epilepsy in Chinese children. Epileptic Disord. 2013 Sep;15(3):272-7. doi: 10.1684/epd.2013.0603.</citation>
    <PMID>23996681</PMID>
  </results_reference>
  <results_reference>
    <citation>Kumari R, Lakhan R, Garg RK, Kalita J, Misra UK, Mittal B. Pharmacogenomic association study on the role of drug metabolizing, drug transporters and drug target gene polymorphisms in drug-resistant epilepsy in a north Indian population. Indian J Hum Genet. 2011 May;17 Suppl 1:S32-40. doi: 10.4103/0971-6866.80357.</citation>
    <PMID>21747585</PMID>
  </results_reference>
  <results_reference>
    <citation>Kasperaviciūte D, Sisodiya SM. Epilepsy pharmacogenetics. Pharmacogenomics. 2009 May;10(5):817-36. doi: 10.2217/pgs.09.34. Review.</citation>
    <PMID>19450130</PMID>
  </results_reference>
  <results_reference>
    <citation>Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, Moshé SL, Perucca E, Wiebe S, French J. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010 Jun;51(6):1069-77. doi: 10.1111/j.1528-1167.2009.02397.x. Epub 2009 Nov 3. Erratum in: Epilepsia. 2010 Sep;51(9):1922.</citation>
    <PMID>19889013</PMID>
  </results_reference>
  <results_reference>
    <citation>Lakhan R, Kumari R, Misra UK, Kalita J, Pradhan S, Mittal B. Differential role of sodium channels SCN1A and SCN2A gene polymorphisms with epilepsy and multiple drug resistance in the north Indian population. Br J Clin Pharmacol. 2009 Aug;68(2):214-20. doi: 10.1111/j.1365-2125.2009.03437.x.</citation>
    <PMID>19694741</PMID>
  </results_reference>
  <results_reference>
    <citation>Lorigados Pedre L, Morales Chacón LM, Orozco Suárez S, Pavón Fuentes N, Estupiñán Díaz B, Serrano Sánchez T, García Maeso I, Rocha Arrieta L. Inflammatory mediators in epilepsy. Curr Pharm Des. 2013;19(38):6766-72. Review.</citation>
    <PMID>23530510</PMID>
  </results_reference>
  <results_reference>
    <citation>Manna I, Gambardella A, Bianchi A, Striano P, Tozzi R, Aguglia U, Beccaria F, Benna P, Campostrini R, Canevini MP, Condino F, Durisotti C, Elia M, Giallonardo AT, Iudice A, Labate A, La Neve A, Michelucci R, Muscas GC, Paravidino R, Zaccara G, Zucca C, Zara F, Perucca E. A functional polymorphism in the SCN1A gene does not influence antiepileptic drug responsiveness in Italian patients with focal epilepsy. Epilepsia. 2011 May;52(5):e40-4. doi: 10.1111/j.1528-1167.2011.03097.x.</citation>
    <PMID>21561445</PMID>
  </results_reference>
  <results_reference>
    <citation>Marchi N, Granata T, Freri E, Ciusani E, Ragona F, Puvenna V, Teng Q, Alexopolous A, Janigro D. Efficacy of anti-inflammatory therapy in a model of acute seizures and in a population of pediatric drug resistant epileptics. PLoS One. 2011 Mar 28;6(3):e18200. doi: 10.1371/journal.pone.0018200.</citation>
    <PMID>21464890</PMID>
  </results_reference>
  <results_reference>
    <citation>Pohlmann-Eden B, Weaver DF. The puzzle(s) of pharmacoresistant epilepsy. Epilepsia. 2013 May;54 Suppl 2:1-4. doi: 10.1111/epi.12174.</citation>
    <PMID>23646961</PMID>
  </results_reference>
  <results_reference>
    <citation>Sánchez MB, Herranz JL, Leno C, Arteaga R, Oterino A, Valdizán EM, Nicolás JM, Adín J, Armijo JA. Genetic factors associated with drug-resistance of epilepsy: relevance of stratification by patient age and aetiology of epilepsy. Seizure. 2010 Mar;19(2):93-101. doi: 10.1016/j.seizure.2009.12.004. Epub 2010 Jan 12.</citation>
    <PMID>20064729</PMID>
  </results_reference>
  <results_reference>
    <citation>Téllez-Zenteno JF, Hernández-Ronquillo L, Buckley S, Zahagun R, Rizvi S. A validation of the new definition of drug-resistant epilepsy by the International League Against Epilepsy. Epilepsia. 2014 Jun;55(6):829-34. doi: 10.1111/epi.12633. Epub 2014 May 14.</citation>
    <PMID>24828683</PMID>
  </results_reference>
  <results_reference>
    <citation>Wirrell EC. Predicting pharmacoresistance in pediatric epilepsy. Epilepsia. 2013 May;54 Suppl 2:19-22. doi: 10.1111/epi.12179. Review.</citation>
    <PMID>23646966</PMID>
  </results_reference>
  <results_reference>
    <citation>Walker L, Sills GJ. Inflammation and epilepsy: the foundations for a new therapeutic approach in epilepsy? Epilepsy Curr. 2012 Jan;12(1):8-12. doi: 10.5698/1535-7511-12.1.8.</citation>
    <PMID>22368518</PMID>
  </results_reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 14, 2019</study_first_submitted>
  <study_first_submitted_qc>November 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2019</study_first_posted>
  <last_update_submitted>November 14, 2019</last_update_submitted>
  <last_update_submitted_qc>November 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University Hospital</investigator_affiliation>
    <investigator_full_name>Ahmed Esmael</investigator_full_name>
    <investigator_title>Assistant Prof of Neurology</investigator_title>
  </responsible_party>
  <keyword>Epilepsy, genetic and drug resistant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Drug Resistant Epilepsy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

